in vivo News and Research

RSS

Researchers receive over $1M to study molecular foundations of pancreatic cancer

Alexandros Tzatsos, M.D., Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, was awarded over one million dollars in grants from the National Institutes of Health to study the molecular foundations of pancreatic cancer.

1 Jul 2014

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

Bacteria love to colonize surfaces inside your body, but they have a hard time getting past your rugged, salty skin.

1 Jul 2014

EMA CHMP recommends marketing authorization for GE's VIZAMYL for PET imaging to detect beta amyloids

GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. This opinion recommends the granting of a marketing authorisation for VIZAMYL (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment.

30 Jun 2014

FEI announces the sale of a complete correlative workflow to the University of Maastricht

FEI (NASDAQ: FEIC) announces the sale of a complete correlative workflow to the University of Maastricht. The systems will be installed at the University’s Institute of Nanoscopy, a new research facility that will use the high-resolution microscopes to understand the working mechanisms of protein complexes in an effort to develop new and improved treatment and prevention for disease, such as cancer and tuberculosis.

23 Jun 2014

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, today announced it has entered into a collaboration with Bayer HealthCare (Bayer) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

23 Jun 2014

Dimension Therapeutics closes $30M financing to advance novel gene therapy programs

Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced the closing of a $30 million financing.

23 Jun 2014

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics.

20 Jun 2014

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

When the body receives an injury to the skin, a signal is sent to the brain, which generates a sensation of pain.

20 Jun 2014

Bioengineer wins NIH grant to advance brain-computer interface technology

Less than two years ago, a brain-computer interface designed at the University of Pittsburgh allowed Jan Scheuermann to control a robotic arm solely with her thoughts. Using the arm to bring a chocolate bar to her mouth and taking a bite was a sweet victory for Scheuermann, who has quadriplegia.

19 Jun 2014

Western Oncolytics closes $275,000 in seed funding

Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells.

18 Jun 2014

Researchers identify new mechanism by which normal cells turn malignant in mammary epithelial tissues

A team of researchers led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences, have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast cancer.

17 Jun 2014

New technique to uncover building blocks of kidney regeneration

Doctors and scientists have for years been astonished to observe patients with kidney disease experiencing renal regeneration. The kidney, unlike its neighbor the liver, was universally understood to be a static organ once it had fully developed.

17 Jun 2014

Enhancing vaccine efficiency through encapsulation

A work published in Vaccine, and led by the Institut de Biotecnologia i de Biomedicina (IBB – UAB) and ICN2, studies the biodistribution and immunological efficacy protecting from infection of immunostimulant-loaded nanoliposomes in zebrafish in vivo.

17 Jun 2014

Lipids efficiently kill leukemia cells

T cells use a novel mechanism to fight leukemia. They may recognize unique lipids produced by cancer cells and kill tumor cells expressing these lipid molecules.

17 Jun 2014

Exercise transiently suppresses inflammation in rheumatic disease

Research findings presented today at the European League Against Rheumatism Annual Congress suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease.

12 Jun 2014

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma.

11 Jun 2014

New biometric wearable devices use scattered light to monitor glucose levels and pulse

Monitoring a patient's vital signs and other physiological parameters is a standard part of medical care, but, increasingly, health and fitness-minded individuals are looking for ways to easily keep their own tabs on these measurements. Enter the biometric watch.

11 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19.

9 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

in vivo News and Research

Researchers receive over $1M to study molecular foundations of pancreatic cancer

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

EMA CHMP recommends marketing authorization for GE's VIZAMYL for PET imaging to detect beta amyloids

FEI announces the sale of a complete correlative workflow to the University of Maastricht

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics closes $30M financing to advance novel gene therapy programs

SCLC tumours replicated in mice from patients' CTCs

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

Bioengineer wins NIH grant to advance brain-computer interface technology

Western Oncolytics closes $275,000 in seed funding

Researchers identify new mechanism by which normal cells turn malignant in mammary epithelial tissues

New technique to uncover building blocks of kidney regeneration

Enhancing vaccine efficiency through encapsulation

Lipids efficiently kill leukemia cells

Exercise transiently suppresses inflammation in rheumatic disease

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

New biometric wearable devices use scattered light to monitor glucose levels and pulse

Celsion signs definitive asset purchase agreement to acquire EGEN

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News